Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Meta Platforms Inc (META) vs Revvity Inc (RVTY) Price & Performance

Meta Platforms IncTrade
Revvity IncTrade

Price performance (Past 24H)

Key statistics

Meta Platforms Inc vs Revvity Inc — how do they compare? Meta Platforms Inc trades at $582.54 (market cap $1.53T), while Revvity Inc trades at $116.27 (market cap $12.91B). The key difference: Meta Platforms Inc is far larger — about 118.5× Revvity Inc's market cap, and Meta Platforms Inc pays the higher dividend (0.35%). Which is the better fit depends on your goals.

METARVTY
Market Cap
$1.53T$12.91B
Volume
24,093,972
Sector
MediaTechnology
52-Week High
$790.00$117.75
52-Week Low
$525.72$82.26
Enterprise Value
$1.55T$15.23B
Dividend Yield
0.35%0.24%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Meta Platforms Inc

META stock trades at $581.30, down 2.29% over 24 hours. The technical picture is neutral, with the price near key support at $580. Fundamentally, the company reported strong revenue of $200.97B for 2025 and a net income margin of 29.84%, though Q2 2026 EPS missed expectations. Recent news highlights the launch of the Muse Spark AI model and a significant legal ruling in Massachusetts.

The outlook is positive, supported by a strong analyst consensus (79% Buy) and a $761.95 price target. Key opportunities include AI monetization and revenue growth, while risks involve high capital expenditure, legal challenges, and competitive pressures in the social media and AI sectors.

Revvity Inc

RVTY trades at $116.10, up 0.07% on the day, with a bullish technical signal and strong earnings beats in recent quarters. The company reported Q2 2026 EPS of $1.41, surpassing the $1.21 estimate, and raised its full-year outlook due to robust diagnostics demand. Revenue remains steady around $2.9 billion, with a net income margin of 8.16%. Analyst consensus is a Buy with a $120.50 price target, and recent news highlights product launches like the SuperFlex prenatal system and high-throughput TB testing platform.

The outlook for RVTY is positive, supported by earnings momentum and strategic innovations, but investors face risks from high valuation multiples and competitive pressures in the healthcare sector. The stock's proximity to its consensus target suggests limited near-term upside, requiring careful monitoring of execution against raised guidance.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Meta Platforms Inc

Meta Platforms Inc., doing business as Meta and previously known as Facebook Inc. It's a company that acts as a parent platform for Facebook, Messenger, Instagram, Whatsapp, Oculus and other subsidiaries. Among these platforms, Facebook is the number one social media platform in terms of the number of active users.

Read more on META

About Revvity Inc

Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.

Read more on RVTY